Takeda Pharmaceutical Co. Ltd. and Seattle Genetics, Inc. Highlight Post-Hoc Analysis Examining Progression-free Survival With ADCETRIS® (brentuximab vedotin) Versus Prior Therapy at the International Conference on Malignant Lymphoma

Published: Jun 19, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LUGANO, Switzerland--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced data from a post-hoc analysis examining progression-free survival (PFS) following treatment with ADCETRIS® (brentuximab vedotin) versus last prior therapy in patients diagnosed with relapsed or refractory Hodgkin lymphoma (HL) post-autologous stem cell transplant (ASCT) or relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). The data were highlighted during a presentation at the 12th International Conference on Malignant Lymphoma (ICML) being held June 19–22, 2013 in Lugano, Switzerland.

Help employers find you! Check out all the jobs and post your resume.

Back to news